Abstract
Iloperidone is an atypical antipsychotic drug of a group referred to as SDAs (serotonin/dopamine receptor antagonists). This antipsychotic was approved by the FDA for the treatment of schizophrenia in the United States in 2009; it is still not available in the Czech Republic.
Iloperidone is as effective as haloperidol in the treatment of schizophrenia. It has a low rate of extrapyramidal and metabolic adverse effects.
Common adverse effects mainly include orthostatic hypotension, dizziness, and a dose-dependent QTc interval prolongation early in the treatment. The efficacy and tolerance of iloperidone were evaluated in relation to genetic markers.
Several nucleotide polymorphisms have been found to be associated with a higher efficacy and an increased risk of QTc interval prolongation.